These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20112275)

  • 1. Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance.
    Fuchs D; Rodriguez A; Eriksson S; Christofferson R; Sundberg C; Azarbayjani F
    Int J Cancer; 2010 Jun; 126(12):2773-89. PubMed ID: 20112275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice.
    Bäckman U; Christofferson R
    Pediatr Res; 2005 May; 57(5 Pt 1):690-5. PubMed ID: 15718357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neuroblastoma xenografts.
    Kaneko S; Ishibashi M; Kaneko M
    Cancer Sci; 2008 Jun; 99(6):1209-17. PubMed ID: 18384433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence.
    Taschner-Mandl S; Schwarz M; Blaha J; Kauer M; Kromp F; Frank N; Rifatbegovic F; Weiss T; Ladenstein R; Hohenegger M; Ambros IM; Ambros PF
    Oncotarget; 2016 Jan; 7(3):3571-86. PubMed ID: 26657295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
    Zins K; Kovatchki D; Lucas T; Abraham D
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777.
    Beauparlant P; Bédard D; Bernier C; Chan H; Gilbert K; Goulet D; Gratton MO; Lavoie M; Roulston A; Turcotte E; Watson M
    Anticancer Drugs; 2009 Jun; 20(5):346-54. PubMed ID: 19369827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor origin of endothelial cells in human neuroblastoma.
    Pezzolo A; Parodi F; Corrias MV; Cinti R; Gambini C; Pistoia V
    J Clin Oncol; 2007 Feb; 25(4):376-83. PubMed ID: 17264333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma.
    Kato H; Ito E; Shi W; Alajez NM; Yue S; Lee C; Chan N; Bhogal N; Coackley CL; Vines D; Green D; Waldron J; Gullane P; Bristow R; Liu FF
    Clin Cancer Res; 2010 Feb; 16(3):898-911. PubMed ID: 20103674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
    Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
    J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models.
    Morowitz MJ; Barr R; Wang Q; King R; Rhodin N; Pawel B; Zhao H; Erickson SA; Sheppard GS; Wang J; Maris JM; Shusterman S
    Clin Cancer Res; 2005 Apr; 11(7):2680-5. PubMed ID: 15814649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target.
    Balamuth NJ; Wood A; Wang Q; Jagannathan J; Mayes P; Zhang Z; Chen Z; Rappaport E; Courtright J; Pawel B; Weber B; Wooster R; Sekyere EO; Marshall GM; Maris JM
    Cancer Res; 2010 Apr; 70(7):2749-58. PubMed ID: 20233875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
    Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
    Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.
    Komar-Stossel C; Gross E; Dery E; Corchia N; Meir K; Fried I; Abramovitch R
    PLoS One; 2014; 9(3):e90224. PubMed ID: 24603724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
    Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of inhibitor-of-apoptosis protein (IAP) livin by neuroblastoma cells: correlation with prognostic factors and outcome.
    Kim DK; Alvarado CS; Abramowsky CR; Gu L; Zhou M; Soe MM; Sullivan K; George B; Schemankewitz E; Findley HW
    Pediatr Dev Pathol; 2005; 8(6):621-9. PubMed ID: 16328668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death.
    Sagulenko V; Muth D; Sagulenko E; Paffhausen T; Schwab M; Westermann F
    Carcinogenesis; 2008 Oct; 29(10):1869-77. PubMed ID: 18566016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
    Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
    J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bmi-1 is essential for the tumorigenicity of neuroblastoma cells.
    Cui H; Hu B; Li T; Ma J; Alam G; Gunning WT; Ding HF
    Am J Pathol; 2007 Apr; 170(4):1370-8. PubMed ID: 17392175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
    Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.